Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations

Published:2023-01 Issue:1 Volume:10 Page:e71-e78
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Garcia-Manero Guillermo

Publisher

Elsevier BV

Subject

Hematology

Reference45 articles.

1. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B;Silverman;J Clin Oncol,2002

2. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer,2006

3. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study;Garcia-Manero;Blood,2020

4. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast percentage AML;Adès;Blood Adv,2022

5. Myelodysplastic syndromes;Tefferi;N Engl J Med,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Breaking Boundaries: Immunotherapy for Myeloid Malignancies;Cancers;2024-08-06

3. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07

4. TP53 in MDS and AML: Biological and clinical advances;Cancer Letters;2024-04

5. A 2‐week treatment with 5‐azacytidine improved the hypercontractility state in prostate from obese mice: Role of the nitric oxide‐cyclic guanosine monophosphate signalling pathway;Clinical and Experimental Pharmacology and Physiology;2024-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3